CCG-1423

CCG-1423 is a small-molecule inhibitor of the Rho/MRTF/SRF transcriptional signaling pathway. Originally developed by Kyoto University, it functions by inhibiting Serum Response Factor (SRF)-mediated transcription, which is critical for the expression of genes involved in cell proliferation, migration, and myofibroblast differentiation. The compound has been shown to bind directly to Pirin, an iron-dependent cotranscription factor, which is essential for its inhibitory activity. In preclinical studies, CCG-1423 has demonstrated efficacy in models of melanoma, prostate cancer, cardiac fibrosis, and atherosclerosis. It is widely used as a research tool to study Rho-dependent signaling but has not yet entered clinical trials.